DekaBank Deutsche Girozentrale invests in Recursion Pharmaceuticals

Trending News 🌥️

Recursion Pharmaceuticals Intrinsic Value – Recursion Pharmaceuticals ($NASDAQ:RXRX), Inc. has gained a new shareholder, DekaBank Deutsche Girozentrale, who has purchased $310,000 worth of stock in the company. Recursion Pharmaceuticals is a leading biopharmaceutical company that uses artificial intelligence and machine learning to develop new treatments for diseases. The company has gained a lot of attention and investment due to its unique approach to drug development.

DekaBank Deutsche Girozentrale is one of the largest banks in Germany. The investment from DekaBank will help Recursion Pharmaceuticals continue its groundbreaking work in developing new treatments for diseases. With the new investment, the company will be able to continue its research and development efforts and bring new treatments to patients sooner.

Share Price

RECURSION PHARMACEUTICALS stock opened at $10.3 and closed at $9.6 on Friday, down by 4.1% from its last closing price of $10.0.

VI Analysis – Recursion Pharmaceuticals Intrinsic Value Calculator

Recursion Pharmaceuticals is a biotechnology company that uses artificial intelligence to discover and develop new drugs. The company’s technology platform consists of two main components: a data-mining engine that analyzes large data sets to identify potential new drug targets, and a machine-learning system that optimizes drug candidates. The company is headquartered in Salt Lake City, Utah.

VI Peers

The company was founded in 2013 by Christopher R. Gibson and Brendan Frey. Vor Biopharma Inc, EQRx Inc, and Lantern Pharma Inc are all competitors of Recursion Pharmaceuticals Inc.

– Vor Biopharma Inc ($NASDAQ:VOR)

Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with serious and life-threatening diseases. The company’s lead product candidate is VOR51, a first-in-class immunotherapy for the treatment of solid tumors. Vor Biopharma is also developing VOR33, a novel immunotherapy for the treatment of hematologic malignancies, and VOR19, a novel immunotherapy for the treatment of autoimmune diseases.

– EQRx Inc ($NASDAQ:EQRX)

EQRx is a biopharmaceutical company that focuses on the development of innovative therapies for patients with serious diseases. The company has a market cap of $2.42 billion and a return on equity of -12.39%. EQRx is headquartered in Cambridge, Massachusetts.

– Lantern Pharma Inc ($NASDAQ:LTRN)

Lantern Pharma Inc has a market cap of 46.57M as of 2022. The company’s return on equity is 16.74%.

Lantern Pharma Inc is a clinical stage biopharmaceutical company specializing in the development of precision medicines for the treatment of cancer. The company’s lead product candidate, LP-100, is a novel targeted therapy in development for the treatment of non-small cell lung cancer.

Summary

DekaBank Deutsche Girozentrale is a leading German banking institution that offers a wide range of financial services to its clients. One of the services that DekaBank offers is investing in cutting-edge companies like Recursion Pharmaceuticals. Recursion Pharmaceuticals is a biotechnology company that uses artificial intelligence and machine learning to develop new drugs and treatments for diseases. The company has made significant progress in its short history, and DekaBank believes that it has the potential to make even more progress in the future.

DekaBank has invested in Recursion Pharmaceuticals because it believes that the company has the potential to revolutionize the way that drugs are developed and approved. The bank is confident that Recursion Pharmaceuticals will be a major player in the pharmaceutical industry in the years to come.